Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy.

[1]  M. Desai,et al.  Management of hypertrophic cardiomyopathy. , 1993, Heart disease and stroke : a journal for primary care physicians.

[2]  C. Autore,et al.  Syncope and Risk of Sudden Death in Hypertrophic Cardiomyopathy , 2009, Circulation.

[3]  B. Gersh,et al.  Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy , 2009, Heart.

[4]  B. Maron,et al.  Sudden Deaths in Young Competitive Athletes: Analysis of 1866 Deaths in the United States, 1980–2006 , 2009, Circulation.

[5]  M. Gold,et al.  Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. , 2008, Journal of the American College of Cardiology.

[6]  B. Maron,et al.  Implantable Defibrillators and Prevention of Sudden Death in Hypertrophic Cardiomyopathy , 2008, Journal of cardiovascular electrophysiology.

[7]  W. Manning,et al.  Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. , 2008, Journal of the American College of Cardiology.

[8]  A. Tajik,et al.  Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. , 2007, European heart journal.

[9]  L. Harris,et al.  Determinants of implantable defibrillator discharges in high-risk patients with hypertrophic cardiomyopathy , 2007, Heart.

[10]  M. Link,et al.  Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. , 2007, JAMA.

[11]  S. Ommen,et al.  Hypertrophic cardiomyopathy, sudden death, and implantable cardiac defibrillators: how low the bar? , 2007, JAMA.

[12]  Dan M. Roden,et al.  ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines , 2006 .

[13]  P. Elliott,et al.  Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. , 2006, European heart journal.

[14]  Barry J Maron,et al.  Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interd , 2006, Circulation.

[15]  R. Berger,et al.  Are Implantable Cardioverter Defibrillator Shocks a Surrogate for Sudden Cardiac Death in Patients With Nonischemic Cardiomyopathy? , 2006, Circulation.

[16]  Robert G. Hauser,et al.  Lessons From the Failure and Recall of an Implantable Cardioverter-Defibrillator , 2005, Circulation.

[17]  C. Semsarian,et al.  Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy. , 2004, The American journal of cardiology.

[18]  Barry J Maron,et al.  American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G , 2003, Journal of the American College of Cardiology.

[19]  B. Maron.  Contemporary considerations for risk stratification, sudden death and prevention in hypertrophic cardiomyopathy , 2003, Heart.

[20]  M. Link,et al.  Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. , 2003, Circulation.

[21]  B. Maron,et al.  Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. , 2003, The New England journal of medicine.

[22]  B. Maron.  Hypertrophic cardiomyopathy: a systematic review. , 2002, JAMA.

[23]  E. Behr,et al.  Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death , 2002, Heart.

[24]  P. Elliott,et al.  Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy , 2001, The Lancet.

[25]  P. Elliott,et al.  Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. , 2000, Journal of the American College of Cardiology.

[26]  B. Maron,et al.  Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. , 2000, Circulation.

[27]  B. Maron,et al.  Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[28]  M. Link,et al.  Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[29]  B. Maron,et al.  Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. , 1999, JAMA.

[30]  B. Maron,et al.  Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. , 1995, Journal of the American College of Cardiology.

[31]  B. Maron,et al.  Prevalence, Clinical Significance, and Natural History of Left Ventricular Apical Aneurysms in Hypertrophic Cardiomyopathy , 2009 .